publication venue for
- Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma. 6:989-989. 2020
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer. 6:831-831. 2020
- Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. 6:505-505. 2020
- Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With “Good Prognosis” Rectal Cancer Eligible for Primary Surgery. 5:961-961. 2019
- Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy. 5:664-664. 2019
- Therapeutic Options for Neuroendocrine Tumors. 5:480-480. 2019
- Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. 4:1059-1059. 2018
- Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma. 3:913-913. 2017
- Effect of Radiotherapy on Painful Bone Metastases. 3:953-953. 2017
- Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma. 3:366-366. 2017
- Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. 3:220-220. 2017
- Clarifying Assumptions and Outcomes in Cost-Effectiveness Analyses—Reply. 2:278-278. 2016
- Cost-effectiveness of Lung Cancer Screening in Canada. 1:807-807. 2015
- Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. 1:359-359. 2015